Research ArticleClinical Guidelines and Primary Care

Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective

James Conniff and Ann Evensen
The Journal of the American Board of Family Medicine January 2016, 29 (1) 143-151; DOI: https://doi.org/10.3122/jabfm.2016.01.150223

References

  1. 1.↵
    Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2013. HIV surveillance report, vol. 25. Last updated February 23, 2015. Available from: http://www.cdc.gov/hiv/library/reports/surveillance/2013/surveillance_Report_vol_25.html/. Accessed November 23, 2015.
  2. 2.↵
    1. Chang LW,
    2. Serwadda D,
    3. Quinn TC,
    4. Wawer MJ,
    5. Gray RH,
    6. Reynolds SJ
    . Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Lancet Infect Dis 2013;13:65–76.
    OpenUrlPubMed
  3. 3.↵
    1. O'Connor EA,
    2. Lin JS,
    3. Burda BU,
    4. Henderson JT,
    5. Walsh ES,
    6. Whitlock EP
    . Behavioral sexual risk-reduction counseling in primary care to prevent sexually transmitted infections: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2014;161:874–83.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Sherin K,
    2. Klekamp BG,
    3. Beal J,
    4. Martin N
    . What is new in HIV infection? Am Fam Physician 2014;89:265–72.
    OpenUrlPubMed
  5. 5.↵
    1. Vermund SH,
    2. Tique JA,
    3. Cassell HM,
    4. Pask ME,
    5. Ciampa PJ,
    6. Audet CM
    . Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr 2013;63(Suppl 1):S12–25.
    OpenUrlPubMed
  6. 6.↵
    US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014. A clinical practice guideline. Atlanta: Centers for Disease Control and Prevention. Available from: http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf#sthash.g4lZ3uzp.dpuf/. Accessed January 16, 2015.
  7. 7.↵
    1. Grant RM,
    2. Lama JR,
    3. Anderson PL,
    4. et al
    . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587–99.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Baeten JM,
    2. Donnell D,
    3. Ndase P,
    4. et al
    . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399–410.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Thigpen MC,
    2. Kebaabetswe PM,
    3. Paxton LA,
    4. et al
    . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423–34.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Choopanya K,
    2. Martin M,
    3. Suntharasamai P,
    4. et al
    . Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083–90.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Grohskopf LA,
    2. Chillag KL,
    3. Gvetadze R,
    4. et al
    . Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013;64:79–86.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Okwundu CI,
    2. Uthman OA,
    3. Okoromah CA
    . Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 2012;7:CD007189.
    OpenUrlPubMed
  13. 13.↵
    International AIDS Society Conference 2015. The Vancouver consensus. Available from: http://vancouverconsensus.org/. Accessed September 8, 2015.
  14. 14.↵
    1. Mimiaga MJ,
    2. White JM,
    3. Krakower DS,
    4. Biello KB,
    5. Mayer KH
    . Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. AIDS Care 2014;26:684–93.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Karris MY,
    2. Beekmann SE,
    3. Mehta SR,
    4. Anderson CM,
    5. Polgreen PM
    . Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis 2014;58:704–12.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Flash C,
    2. Landovitz R,
    3. Giler RM,
    4. et al
    . Two years of Truvada for pre-exposure prophylaxis utilization in the US. J Int AIDS Soc 2014;17(4 Suppl 3):19730.
    OpenUrlPubMed
  17. 17.↵
    1. Krakower D,
    2. Mayer KH
    . What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med 2012;157:490–7.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. McCormack S,
    2. Dunn D
    . Pragmatic open-label randomised trial of preexposure prophylaxis in MSM: the PROUD study. Paper presented at: Conference on Retroviruses and Opportunistic Infections, Seattle, WA (February 23–26, 2015). Available from: http://www.croiconference.org/sessions/pragmatic-open-label-randomised-trial-preexposure-prophylaxis-proud-study. Accessed September 3, 2015.
  19. 19.↵
    1. Liu A,
    2. Cohen S,
    3. Vittinghoff E,
    4. et al
    . Adherence, sexual behavior and HIV/STI incidence among men who have sex with men (MSM) and transgender women (TGW) in the US PrEP demonstration (Demo) project. Abstract TUAC0202. Paper presented at: 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Vancouver (July 19–22, 2015).
  20. 20.↵
    1. Peterson L,
    2. Taylor D,
    3. Roddy R,
    4. et al
    . Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007;2(5):e27.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Van Damme L,
    2. Corneli A,
    3. Ahmed K,
    4. et al
    . Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411–22.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Marrazzo JM,
    2. Ramjee G,
    3. Richardson BA,
    4. et al
    . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015;372:509–18.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Abdool Karim Q,
    2. Abdool Karim SS,
    3. Frohlich JA,
    4. et al
    . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168–74.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Baeten JD,
    2. Heffron R,
    3. Kidoguchi L,
    4. et al
    . Near elimination of HIV transmission in the Partners Demonstration Project of PrEP and ART in Uganda and Kenya. Paper presented at: Conference on Retroviruses and Opportunistic Infections, Seattle, WA (February 23–26, 2015). Available from: http://www.croiconference.org/sessions/near-elimination-hiv-transmission-demonstration-project-prep-and-art. Accessed September 3, 2015.
  25. 25.↵
    Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute of Mental Health. Pre-exposure prophylaxis in YMSM. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT01033942. Accessed November 23, 2015.
  26. 26.↵
    Eunice Kennedy Shriver National Institute of Child Health and Human Development. An open label demonstration project and phase II safety study of pre-exposure prophylaxis use among 15 to 17 year old young men who have sex with men (YMSM). Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT01769456. Accessed November 23, 2015.
  27. 27.↵
    National Institute of Allergy and Infectious Diseases. Evaluating the acceptability, safety, and use of daily truvada pre-exposure prophylaxis in healthy, HIV-uninfected adolescents. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT02213328. Accessed November 23, 2015.
  28. 28.↵
    Eunice Kennedy Shriver National Institute of Child Health and Human Development. An open label demonstration project and phase II safety study of pre-exposure prophylaxis. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT01769456. Accessed November 23, 2015.
  29. 29.↵
    National Institute of Allergy and Infectious Diseases. The ADAPT study: use of emtricitabine and tenofovir disoproxil fumarate for pre-exposure prophylaxis (PrEP). In: Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT01327651. Accessed November 23, 2015.
  30. 30.↵
    French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis. On demand antiretroviral pre-exposure prophylaxis for HIV infection in men who have sex with men. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT01473472. Accessed November 23, 2015.
  31. 31.↵
    Bill and Melinda Gates Foundation, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Phase II safety and acceptability of an investigational injectable product, TMC278LA, for pre-exposure prophylaxis. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT02165202. Accessed November 23, 2015.
  32. 32.↵
    ViiV Healthcare, GlaxoSmithKline. Study to evaluate the safety tolerability and acceptability of long acting injections of the human immunodeficiency virus (HIV) integrase inhibitor, GSK1265744, in HIV uninfected men (ECLAIR). Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/show/NCT02076178. Accessed November 23, 2015.
  33. 33.↵
    1. Molina J-M,
    2. Capitant C,
    3. Spire B,
    4. et al
    . On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Abstract presented at: Conference on Retroviruses and Opportunistic Infections, Seattle, WA (February 23–26, 2015). Available from: http://www.croiconference.org/sessions/demand-prep-oral-tdf-ftc-msm-results-anrs-ipergay-trial. Accessed September 3, 2015.
  34. 34.↵
    ACOG Committee opinion no 595: Committee on Gynecologic Practice: preexposure prophylaxis for the prevention of human immunodeficiency virus. Obstet Gynecol. 2014;123:1133–6.
    OpenUrlPubMed
  35. 35.↵
    1. Baeten JM,
    2. Grant R
    . Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep 2013;10:142–51.
    OpenUrlCrossRef
  36. 36.↵
    1. Cohen MS,
    2. Baden LR
    . Preexposure prophylaxis for HIV–where do we go from here? N Engl J Med 2012;367:459–61.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Abdool Karim SS,
    2. Gray GE,
    3. Martinson N
    . Clinical decisions. Preexposure prophylaxis for HIV prevention. N Engl J Med 2012;367:462–5.
    OpenUrlPubMed
  38. 38.↵
    1. Marcus JL,
    2. Buisker T,
    3. Horvath T,
    4. et al
    . Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions. HIV Med 2014;15:385–95.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Plosker GL
    . Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Drugs 2013;73:279–91.
    OpenUrlCrossRefPubMed
  40. 40.↵
    New York State Department of Health AIDS Institute. Guidance for the use of pre-exposure prophylaxis (PrEP) to prevent HIV transmission. October 2015. Available from: http://www.hivguidelines.org/wp-content/uploads/2015/10/PrEP-Guidance_10-14-15.pdf. Accessed November 23, 2015.
  41. 41.↵
    1. Amico KR,
    2. Mansoor LE,
    3. Corneli A,
    4. Torjesen K,
    5. van der Straten A
    . Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav 2013;17:2143–55.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Landovitz RJ
    . PrEP for HIV prevention: What we know and what we still need to know for implementation. Paper presented at: Conference on Retroviruses and Opportunistic Infections, Seattle, WA (February 23–26, 2015). Available from http://www.croiwebcasts.org/console/player/25535. Accessed July 13, 2015.
  43. 43.↵
    1. Kasonde M,
    2. Niska RW,
    3. Rose C,
    4. Henderson FL,
    5. Segolodi TM,
    6. et al
    . Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One 2014;9(3):e90111.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Liu AY,
    2. Vittinghoff E,
    3. Sellmeyer DE,
    4. et al
    . Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011;6(8):e23688.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Solomon MM,
    2. Lama JR,
    3. Glidden DV,
    4. et al
    . Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS 2014;28:851–9.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Tripathi A,
    2. Whiteside YO,
    3. Duffus WA
    . Perceptions and attitudes about preexposure prophylaxis among seronegative partners and the potential of sexual disinhibition. South Med J 2013;106:558–64.
    OpenUrlPubMed
  47. 47.↵
    1. Juusola JL,
    2. Brandeau ML,
    3. Owens DK,
    4. Bendavid E
    . The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med 2012;156:541–50.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    AIDS Foundation of Chicago. Truvada track–monitoring insurance and Medicaid coverage of Truvada for PrEP. My PrEP Experience. 2015. Available from: http://myprepexperience.blogspot.com/p/truvada-track.html. Accessed September 3, 2015.
  49. 49.↵
    New York City Department of Health and Mental Hygiene. Health department launches new PrEP & PEP campaign: new ways to prevent HIV. Press release no. 003–15. January 12, 2015. Available from: http://www.nyc.gov/html/doh/html/pr2015/pr003–15.shtml. Accessed September 3, 2015.
  50. 50.↵
    New York City Department of Health and Mental Hygiene. New York City biomedical HIV prevention referral list. Available from: http://www.nyc.gov/html/doh/downloads/pdf/ah/provider-clinical-site-checklist.pdf. Accessed September 3, 2015.
  51. 51.↵
    1. Jay JS,
    2. Gostin LO
    . Ethical challenges of preexposure prophylaxis for HIV. JAMA 2012;308:867–8.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Campbell JD,
    2. Herbst JH,
    3. Koppenhaver RT,
    4. Smith DK
    . Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV. Am J Prev Med 2013;44(1 Suppl 2):S63–9.
    OpenUrlPubMed
  53. 53.↵
    1. Wood LV
    . Why I voted “no” to Truvada PrEP. Ann Intern Med 2012;157:519–20.
    OpenUrlPubMed
  54. 54.↵
    1. Hurt CB,
    2. Eron JJ Jr.,
    3. Cohen MS
    . Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis 2011;53:1265–70.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Healy P
    . A lion still roars, with gratitude: Larry Kramer lives to see his ‘Normal Heart’ filmed for TV. New York Times, May 21, 2014.
  56. 56.↵
    1. Murphy T
    . Sex without fear: The new pill that could revolutionize gay life is reawakening old arguments. New York Magazine, July 13, 2014.
  57. 57.↵
    1. McNeil D
    . Are we ready for H.I.V.'s sexual revolution? New York Times, May 23, 2014.
  58. 58.↵
    1. Sullivan A
    . Hey, wait a minute, Mr. Kramer. The Dish [Internet]. May 27, 2014. Available from: http://dish.andrewsullivan.com/2014/05/27/hey-wait-a-minute-mr-kramer/. Accessed July 13, 2015.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords